rs1883832 — CD40 Kozak -1C>T

Kozak sequence variant at position −1 of the CD40 start codon — the C allele boosts translational efficiency, producing ~30% more CD40 protein and increasing susceptibility to Graves' disease; the T allele reduces CD40 expression and independently elevates risk for multiple sclerosis and Crohn's disease

See your personal result for CD40

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CD40 Kozak Variant — A Molecular Dimmer Switch on Immune Activation

The CD40 gene encodes a co-stimulatory receptor11 co-stimulatory receptor
CD40 belongs to the TNF receptor superfamily; it is constitutively expressed on B cells, dendritic cells, monocytes, and macrophages that sits at the intersection of innate and adaptive immunity. When CD40 on an antigen-presenting cell binds its ligand CD40L (CD154) on activated T helper cells, it triggers B-cell proliferation, immunoglobulin class switching, germinal center formation, and dendritic cell maturation — the core machinery of antibody-mediated adaptive immune responses.

The rs1883832 variant sits at position −1 of the CD40 Kozak sequence, a short stretch of nucleotides flanking the AUG start codon that controls how efficiently ribosomes initiate translation. This is a mechanistically precise variant: it does not change what the CD40 protein does, nor does it alter how much CD40 mRNA is transcribed. Instead, it adjusts the efficiency with which existing CD40 mRNA is converted into protein — essentially a molecular rheostat on the immune system's co-stimulatory signal strength.

The Mechanism

The C allele at position −1 creates a stronger Kozak consensus sequence, enabling more efficient ribosomal recognition of the start codon and higher rates of CD40 protein synthesis. The T allele weakens this translational initiation signal22 translational initiation signal
Kozak sequences (GCCACCATGG) guide ribosomes to the start codon; the −1 position is a critical determinant of translation initiation efficiency.

Jacobson et al. (2005) demonstrated this mechanism with multiple independent methods. B cells from individuals with the CT genotype expressed 13.3% less surface CD40 than CC homozygotes; TT individuals showed 39.4% less. In a fibroblast transfection system, T-allele constructs produced 32.2% less CD40 protein than C-allele constructs. An in vitro cell-free transcription/translation system confirmed the effect is post-transcriptional: the T allele produces 15.5% less protein from equivalent mRNA. Crucially, CD40 mRNA levels were identical across genotypes — confirming the mechanism is purely translational. The variant is in strong linkage disequilibrium33 linkage disequilibrium
LD r²=0.95 with rs4810485 (intronic CD40 variant), meaning they are almost always co-inherited as a single haplotype in Europeans, but their mechanisms are independent: rs1883832 acts at translation, rs4810485 acts via an intronic regulatory element.

The Evidence

Graves' disease is the condition with the strongest and most replicated association. The C allele is the risk allele: Jacobson et al. originally identified this variant in a Graves' disease GWAS44 Jacobson et al. originally identified this variant in a Graves' disease GWAS
A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation. J Clin Endocrinol Metab, 2005, and it has been robustly replicated across ethnicities. A meta-analysis of 40 articles across immune-related diseases55 meta-analysis of 40 articles across immune-related diseases
Association between CD40 rs1883832 and immune-related diseases susceptibility: A meta-analysis. Oncotarget, 2017 found the T allele (lower CD40) protective against Graves' disease, especially in Asian populations. Within the Graves' disease subset the protective effect was consistent across Asian (OR 0.700) and Caucasian (OR 0.832) populations. Direction of effect is consistent with the translational mechanism: higher CD40 expression from the C allele amplifies B-cell co-stimulation, promoting thyroid autoantibody production.

Multiple sclerosis and Crohn's disease show the opposite pattern: the minor T allele (lower CD40) is the risk allele for these conditions. In a Spanish cohort of 1,564 MS patients and 1,102 Crohn's patients vs. 2,948 controls66 1,564 MS patients and 1,102 Crohn's patients vs. 2,948 controls
CD40: Novel Association with Crohn's Disease and Replication in Multiple Sclerosis Susceptibility. PLoS One, 2010, the T allele associated with MS (OR 1.12, p=0.025) and Crohn's disease (OR 1.19, p=0.002) but not ulcerative colitis (OR 1.04, p=0.5). This bidirectional association — where C allele promotes antibody-mediated diseases and T allele promotes T-cell-driven inflammatory diseases — is biologically plausible: CD40-CD40L signaling has distinct downstream consequences depending on cellular context. The same meta-analysis confirmed MS risk: OR 1.175 (95% CI 1.093–1.263) across 3,851 MS cases and 4,368 controls.

Coronary heart disease is an emerging third disease axis. The C allele has been associated with elevated soluble CD40L (sCD40L) levels and atherosclerotic risk in multiple case-control studies, with the biological rationale that higher CD40 expression on platelets and endothelial cells amplifies inflammatory signaling in arterial walls. A 2020 review designated rs1883832 as a CD40 SNP for predicting coronary heart disease77 designated rs1883832 as a CD40 SNP for predicting coronary heart disease
rs1883832: a CD40 single-nucleotide polymorphism for predicting coronary heart disease in humans. Cardiovasc Res, 2020.

Practical Actions

The actionable implications depend on genotype direction. For CC carriers, the dominant concern is autoantibody-driven autoimmunity — particularly thyroid (Graves' disease), and context-dependent risk for seropositive connective tissue diseases. The variant's strong LD with rs4810485 means the two CD40 findings are nearly identical in most individuals.

For TT carriers, the concern shifts to T-cell-driven inflammatory disease — Crohn's disease and MS risk are modestly elevated. This minority genotype (~7% of Europeans) requires attention to early gastrointestinal and neurological symptoms rather than autoantibody surveillance.

Interactions

rs1883832 is in near-complete linkage disequilibrium (r²=0.95) with the intronic CD40 variant rs4810485. Most individuals who carry rs1883832-C also carry rs4810485-G, and both alleles independently contribute to higher CD40 expression through different mechanisms. The haplotype effect is additive: the combined C-G haplotype drives the highest CD40 surface expression observed in B cells and monocytes.

PTPN22 rs2476601 (R620W) is a mechanistically complementary autoimmune locus: PTPN22 modulates the T-cell activation threshold while CD40 modulates the co-stimulatory signal received by B cells. Carriers of both rs2476601-A and rs1883832-C drive adaptive immune hyperactivation from two independent angles, with additive risk for seropositive autoimmune conditions.

CD40 interacts with the NF-kB pathway via TRAF3 and TRAF6 downstream signaling. TNFAIP3 (A20, rs6920220) is the primary negative regulator of CD40-NF-kB signaling; the rs6920220-G risk allele impairs A20-mediated braking, potentially amplifying the downstream consequences of elevated CD40 expression in CC carriers.

Genotype Interpretations

What each possible genotype means for this variant.

CT Intermediate CD40 Expression Intermediate

One C allele gives intermediate CD40 levels — modestly elevated Graves' disease and autoimmune susceptibility

You carry one C allele and one T allele at the CD40 Kozak sequence. Heterozygotes show intermediate CD40 surface expression — approximately 13% less than CC homozygotes, but substantially more than TT carriers. The CT genotype occurs in approximately 38% of European individuals. Graves' disease risk is intermediate between CC and TT, consistent with the codominant effect of this translational variant. The meta-analysis across 17 studies confirmed a graded protective effect of T allele dose: CT carriers have meaningfully lower Graves' disease risk than CC but higher risk than TT. For MS and Crohn's disease, CT is similarly intermediate between the extremes.

CC High CD40 Expression High Risk

Two C alleles drive highest CD40 translational output — elevated risk for Graves' disease and autoantibody-driven conditions

The mechanistic proof is unusually solid for a non-coding variant. Jacobson et al. 2005 demonstrated using three independent assays — B cell surface protein quantification, fibroblast transfection, and in vitro cell-free translation — that the C allele consistently produces more CD40 protein without changing mRNA levels, confirming the effect is purely translational. This mechanistic clarity, combined with consistent replication across ethnically diverse Graves' disease cohorts and confirmation in a 17-study meta-analysis, elevates this beyond a statistical association.

Clinically, CC genotype confers the same risk direction as rs4810485-GG (its strong LD partner, r²=0.95) — both mark the high-CD40-expression state. Most CC individuals also carry rs4810485-GG, making the combined haplotype the strongest CD40-expression biomarker available. Risk is not deterministic: the majority of CC individuals never develop Graves' disease, and HLA alleles, CTLA4 variants, and environmental factors (smoking, iodine exposure, stress) are important modifiers. However, when thyroid symptoms arise, CC status provides meaningful biological context.

TT Low CD40 Expression Decreased

Two T alleles reduce CD40 translational output — protected against Graves' disease but modestly elevated risk for multiple sclerosis and Crohn's disease

The bidirectional risk of this variant reflects the context-dependent roles of CD40 signaling. In B-cell-mediated autoimmunity (Graves' disease, seropositive RA, SLE), high CD40 expression amplifies germinal center reactions and autoantibody production — so low CD40 (TT) is protective. In gut and CNS inflammation (Crohn's disease, MS), lower CD40 expression on dendritic cells may impair immune regulation or alter T-cell subset balance in ways that increase tissue-specific inflammatory risk. This opposing directionality is consistent with the established complexity of CD40 biology: it serves both pro-inflammatory and regulatory immune functions depending on the cell type, cytokine milieu, and anatomical context.

TT carriers at ~7% of Europeans represent a minority genotype that genuinely warrant attention to neurological and gastrointestinal early warning signs rather than thyroid autoimmunity surveillance.